Tanvisha Mody, MD
Endocrinology, Diabetes & Metabolism · New Hyde Park, NYNPI 1124475751
Payments from drug & device makers
Across 142 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Amgen$165
- Alnylam Pharmaceuticals Inc.$123
- Akcea Therapeutics, Inc.$121
- Boehringer Ingelheim$85
- Sanofi-aventis U.S. LLC$82
- plus $528 from 14 others
What the payments were for
- Food & beverage$2,60499%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 94 | $1,536 |
| Amgen | 8 | $165 |
| Alnylam Pharmaceuticals Inc. | 1 | $123 |
| Akcea Therapeutics, Inc. | 1 | $121 |
| Boehringer Ingelheim | 5 | $85 |
| Sanofi-aventis U.S. LLC | 4 | $82 |
| Medtronic | 3 | $67 |
| AbbVie | 3 | $57 |
| Dexcom, Inc. | 3 | $54 |
| Tandem Diabetes Care, Inc. | 3 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $49 |
| Lilly USA, LLC | 3 | $45 |
| Bayer | 2 | $34 |
| Abbott | 2 | $33 |
| AstraZeneca | 2 | $31 |
| Merck | 2 | $30 |
| Zealand Pharma US, Inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Corcept Therapeutics | 1 | $18 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,640 in reported general payments places this provider in the 60th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 218 | $445,034 |
| MounjaroTirzepatide | 131 | $213,920 |
| JardianceEmpagliflozin | 104 | $141,586 |
| TrulicityDulaglutide | 53 | $82,926 |
| FarxigaDapagliflozin Propanediol | 61 | $79,679 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $44,356 |
| JanuviaSitagliptin Phosphate | 34 | $41,765 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $37,259 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $30,904 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $26,185 |
| Cinacalcet Hcl | 22 | $23,564 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 31 | $22,382 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 22 | $19,353 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $18,220 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $7,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,536 | $450,194232 claims |
| Lilly USA, LLCMounjaro, Trulicity | $45 | $296,845184 claims |
| Boehringer IngelheimJardiance | $85 | $141,586104 claims |
| AstraZenecaFarxiga | $31 | $79,67961 claims |
| MerckJanuvia, Janumet Xr, Janumet | $30 | $79,33867 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $82 | $37,25929 claims |
| AbbVieSynthroid | $57 | $7,22178 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $23 | $2,178170 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New Hyde Park
- Kenneth HershonNew Hyde Park$1.9M
- Isaac SachmechiNew Hyde Park$927K
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Michael ShanikSmithtown$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.